10058-F4: Redefining c-Myc-Max Inhibition for Apoptosis and Telomerase Research

Introduction: Targeting c-Myc/Max in Cancer and Beyond

The c-Myc transcription factor is a master regulator of cellular proliferation, differentiation, and metabolism. Its dysregulation is implicated in a wide spectrum of human cancers, making the c-Myc/Max heterodimerization interface a focal point for therapeutic intervention. 10058-F4 (SKU: A1169) has emerged as a groundbreaking tool compound—a small-molecule, cell-permeable c-Myc-Max dimerization inhibitor—enabling researchers to dissect the oncogenic and apoptotic pathways downstream of c-Myc. While previous literature has centered on translational potential and mechanistic insights (see comparative article), this article provides a differentiated, in-depth examination of 10058-F4 as a dual probe for apoptosis and emerging telomerase regulatory pathways, integrating recent DNA repair findings and mitochondrial apoptosis mechanisms for advanced apoptosis assay and cancer biology research.

The c-Myc/Max Heterodimer: A Nexus of Oncogenic Signaling

c-Myc exerts its transcriptional effects by heterodimerizing with Max, enabling sequence-specific DNA binding and activation of genes essential for cell cycle progression and metabolic reprogramming. Aberrant c-Myc/Max activity is a hallmark of many aggressive malignancies, including acute myeloid leukemia (AML) and prostate cancer. Disrupting this critical interaction represents a rational strategy for suppressing oncogenic transcriptional programs.

Mechanism of Action of 10058-F4: Precision Disruption of c-Myc-Max Dimerization

10058-F4 is chemically defined as (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one (MW: 249.35). It selectively inhibits c-Myc-Max dimerization by binding to the c-Myc bHLHZip domain, thereby precluding Max association. This blockade prevents c-Myc/Max complexes from engaging E-box DNA sequences, resulting in transcriptional silencing of c-Myc-driven genes.

• Cellular Uptake: 10058-F4 is cell-permeable and achieves effective intracellular concentrations (solubility: ≥24.9 mg/mL in DMSO, ≥2.64 mg/mL in ethanol).
• Downstream Effects: The disruption of c-Myc/Max heterodimerization leads to rapid declines in c-Myc mRNA and protein levels. This triggers cell cycle arrest and mitochondrial pathway apoptosis, characterized by modulation of Bcl-2 family proteins and cytochrome C release.

Notably, in AML cell lines such as HL-60, U937, and NB-4, 10058-F4 induces apoptosis in a dose-dependent manner, with pronounced effects at 100 μM after 72 hours of treatment. In vivo, intravenous administration in SCID mice bearing human prostate cancer xenografts (DU145, PC-3) demonstrated tumor growth inhibition, albeit with variable efficacy reflective of tumor heterogeneity.

Beyond c-Myc: Integrating Apoptosis and Telomerase Regulation in Mechanistic Research

Linking Mitochondrial Apoptosis and Telomerase Maintenance

Recent advances underscore the importance of apoptosis and DNA repair pathways in regulating not only cancer cell fate but also stem cell longevity and genomic stability. The study by Stern et al. (2024, bioRxiv) reveals that the DNA repair enzyme APEX2 is essential for efficient telomerase reverse transcriptase (TERT) expression in human embryonic stem cells and melanoma lines. This finding adds a new dimension to telomerase biology, showing that DNA repair processes directly intersect with telomerase regulation—a pathway also intimately connected to c-Myc activity, as c-Myc is a known activator of TERT transcription.

By employing 10058-F4 to inhibit c-Myc function, researchers can now probe not only the canonical c-Myc-driven oncogenic and apoptotic pathways but also the indirect modulation of telomerase expression through c-Myc-TERT axis and its cross-talk with APEX2-mediated DNA repair. This enables sophisticated experimental designs in apoptosis assay development and cancer biology, distinguishing this article from prior overviews which mainly focus on direct c-Myc-Max inhibition or translational outlooks (see related synthesis).

Dissecting the c-Myc/Max–TERT–APEX2 Axis

The intersection of c-Myc inhibition and telomerase regulation is particularly relevant for studies of stemness, aging, and cancer cell immortality. The referenced APEX2 study demonstrates that knockdown of APEX2 leads to reduced TERT expression and diminished telomerase activity, with chromatin immunoprecipitation revealing preferential APEX2 binding at MIR sequences within TERT intron 2. As c-Myc is a potent activator of the TERT promoter, 10058-F4 provides a powerful approach to experimentally decouple these regulatory layers, allowing researchers to:

• Assess how c-Myc/Max disruption modulates TERT expression in cancer and stem cell models.
• Interrogate the role of DNA repair enzymes like APEX2 in maintaining TERT expression downstream of c-Myc.
• Design apoptosis assays that simultaneously monitor mitochondrial and telomerase-related endpoints.

This cross-disciplinary view fills a knowledge gap left by existing content, which typically isolates c-Myc/Max inhibition or telomerase regulation, but rarely explores their intersection with DNA repair and cell death pathways.

Comparative Analysis: 10058-F4 Versus Alternative c-Myc Inhibition Strategies

Small-molecule c-Myc inhibitors are a diverse class, but most lack the cell permeability and selectivity of 10058-F4. Alternative strategies include dominant-negative peptides, antisense oligonucleotides, and CRISPR-based gene editing. However, these approaches often face challenges in delivery, specificity, and real-time application in apoptosis assay frameworks.

• 10058-F4 Advantages: Rapid cell entry, reversible action, and ability to titrate dose-response relationships in both in vitro and in vivo models.
• Limitations: Water insolubility (requiring DMSO or ethanol), and potential for off-target effects at high concentrations—a consideration in long-term storage and repeated dosing experimental designs.

While other reviews, such as this in-depth exploration, emphasize structural or translational advances, our discussion uniquely centers on the integration of apoptosis and telomerase biology, and how 10058-F4 can be used to interrogate these convergent mechanisms in real time.

Advanced Applications in Apoptosis, Leukemia, and Prostate Cancer Models

Acute Myeloid Leukemia Research

10058-F4 has demonstrated robust efficacy in AML cell lines, where c-Myc overexpression drives proliferation and blocks differentiation. Dose-dependent apoptosis induction, via the mitochondrial pathway, provides a versatile platform for apoptosis assay optimization. This allows researchers to:

• Quantify cytochrome C release and Bcl-2 family protein modulation.
• Model resistance mechanisms by combining 10058-F4 with DNA repair enzyme modulators (e.g., APEX2 knockdown).
• Evaluate the impact on TERT expression and telomere maintenance in leukemic progenitors.

Prostate Cancer Xenograft Models

In vivo, 10058-F4 inhibits tumor growth in SCID mice bearing DU145 and PC-3 xenografts, although efficacy may vary with tumor subtype and microenvironmental context. This variability offers an experimental advantage for dissecting the interplay between c-Myc/Max activity, apoptosis induction, and telomerase dynamics in complex tumor ecosystems. Researchers can deploy 10058-F4 to:

• Compare mitochondrial apoptosis pathways across xenograft subtypes.
• Integrate telomerase activity measurements with classic tumor growth endpoints.
• Design combinatorial interventions targeting both c-Myc and DNA repair/telomerase axes.

Protocol Guidance and Handling Considerations

10058-F4 is supplied as a solid and should be stored at -20°C. For optimal results, solutions should be freshly prepared in DMSO or ethanol and used promptly, as long-term storage of solutions is not recommended. Due to its water insolubility, ensure thorough mixing and appropriate vehicle controls in all experiments. These best practices enable reproducible results for apoptosis assay and c-Myc transcription factor inhibition studies.

Conclusion and Future Outlook: 10058-F4 as a Dual Probe for Oncogenic and Telomerase Pathways

10058-F4 has transformed the landscape of c-Myc-Max dimerization inhibitor research, enabling precise modulation of both apoptotic and telomerase-related pathways. By leveraging its ability to disrupt c-Myc/Max heterodimer formation, researchers can interrogate mitochondrial apoptosis, cell cycle control, and, crucially, the emerging intersection with telomerase regulation via the APEX2–TERT axis, as highlighted in the latest research (Stern et al., 2024).

This integrative approach sets our discussion apart from earlier mechanistic or translational reviews (see comparative review), offering a more holistic view of how small-molecule c-Myc inhibitors can be deployed in advanced apoptosis and telomerase research. As new data emerges on the cross-talk between DNA repair, telomerase, and oncogenic transcription factors, 10058-F4 will remain an indispensable tool for cancer biology, stem cell research, and drug discovery.

For detailed product information, storage guidelines, and ordering, visit the 10058-F4 product page.